U.S. Army Captain Michael Kelvington, commander of the Battle company, 1-508 Parachute Infantry battalion, 4th Brigade Combat Team, 82nd Airborne Division, bows next to remains of Gulam Dostager, a member of Afghan Local Police who was killed in the blast of an Improvised Explosive Device (IED) during the joint Tor Janda (Black Flag in Pashtu) operation, in Zahri district of Kandahar province, southern Afghanistan May 25, 2012.  REUTERS/Shamil Zhumatov  (AFGHANISTAN - Tags: MILITARY CIVIL UNREST CONFLICT TPX IMAGES OF THE DAY)

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Members of the U.S. Navy Blue Angels fly over the World Trade Center in lower Manhattan as part of the 25th annual Fleet Week celebration in New York, May 23, 2012.  REUTERS/Eduardo Munoz (UNITED STATES - Tags: MILITARY ANNIVERSARY TPX IMAGES OF THE DAY)

Fleet Week

The U.S. Navy takes Manhattan for a week.  Slideshow 

Photo

The SpaceX mission

A privately owned unmanned rocket blasts off on a mission to be the first commercial flight to the International Space Station.  Slideshow 

Astra, UK charity hunt new kind of cancer drug

Related Topics

LONDON | Sat Feb 6, 2010 7:05pm EST

LONDON (Reuters) - AstraZeneca has struck a deal with the commercial arm of a British charity to try and develop a new class of a "cancer metabolism" drugs.

The aim is to exploit the fact cancer cells use energy differently to normal cells, by creating new drugs that control cell metabolism in order to attack tumors whilst sparing normal tissues, the two partners said Sunday.

The three-year alliance will work on a portfolio of projects selected by Cancer Research UK's commercialization and development arm, Cancer Research Technology (CRT).

AstraZeneca will take the most promising projects into pre-clinical and clinical drug development, sharing the risks and potential rewards with CRT.

(Reporting by Ben Hirschler; Editing by Dan Lalor)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.